Glaukos Corp (NYSE:GKOS) has been assigned a consensus recommendation of “Buy” from the twelve analysts that are presently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and eight have issued a buy recommendation on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $41.29.
GKOS has been the topic of several research analyst reports. BMO Capital Markets reissued a “buy” rating on shares of Glaukos in a research note on Monday, December 11th. Cantor Fitzgerald set a $48.00 price target on Glaukos and gave the stock a “buy” rating in a research note on Wednesday, December 27th. ValuEngine lowered Glaukos from a “hold” rating to a “sell” rating in a research note on Monday, February 5th. Zacks Investment Research lowered Glaukos from a “hold” rating to a “sell” rating in a research note on Tuesday, February 13th. Finally, Stifel Nicolaus decreased their price target on Glaukos from $42.00 to $39.00 and set a “buy” rating on the stock in a research note on Monday, February 26th.
In related news, Director Jonathan Silverstein sold 464,583 shares of the company’s stock in a transaction that occurred on Friday, March 2nd. The stock was sold at an average price of $32.29, for a total value of $15,001,385.07. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Orbimed Advisors Llc sold 836,500 shares of the company’s stock in a transaction that occurred on Tuesday, March 6th. The shares were sold at an average price of $32.02, for a total value of $26,784,730.00. The disclosure for this sale can be found here. 16.40% of the stock is currently owned by corporate insiders.
Shares of Glaukos (NYSE:GKOS) traded up $1.64 during trading hours on Friday, hitting $33.76. The stock had a trading volume of 605,431 shares, compared to its average volume of 632,465. The stock has a market cap of $1,115.88, a price-to-earnings ratio of -3,372.63 and a beta of 1.07. Glaukos has a fifty-two week low of $23.08 and a fifty-two week high of $52.48.
Glaukos (NYSE:GKOS) last announced its quarterly earnings results on Wednesday, February 28th. The medical instruments supplier reported $0.03 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.01 by $0.02. The business had revenue of $41.65 million for the quarter, compared to analyst estimates of $40.83 million. Glaukos had a positive return on equity of 4.03% and a negative net margin of 0.06%. The company’s revenue for the quarter was up 25.6% compared to the same quarter last year. equities research analysts anticipate that Glaukos will post -0.38 earnings per share for the current fiscal year.
WARNING: This piece was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://stocknewstimes.com/2018/03/17/glaukos-corp-gkos-given-average-rating-of-buy-by-brokerages.html.
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.